| CABOTEGRAVIR | None | ||
| 600MG/3ML |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| APRETUDE is an HIV-1 integrase strand transfer inhibitor (INSTI) indicated in at-risk adults and adolescents weighing at least 35 kg for PrEP to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP. | |||
|
Yes
| |||
| APRETUDE | Patent 1 | Patent 2 | Patent 3 | Patent 4 |
|---|---|---|---|---|
| *** ********* | ||||
| (**,****)-*-[*,*-**************)******]-*-*******-*-******-*,*-*****-*,*,*,*,**,***-*********[*,*]*******[*,*-*]******[*,*-*]********-*-*********** ****** ** ****-*** ***** | *-[(*,*-**************)******]-*-*******-*-******-*,*-*****-*,*,*,*,**,***-*********[*,*] *******[*,*-*]******[*,*-*]********-*-*********** ****** *** ********* ********** ******** | ************** ************ | ************** ************ |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|